• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Correction to: Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.

作者信息

Marcinak John F, Munsaka Melvin S, Watkins Paul B, Ohira Takashi, Smith Neila

机构信息

Takeda Pharmaceuticals, Takeda Development Center Americas, Inc., 1 Takeda Pkwy, Deerfield, IL, 60015, USA.

Eshelman School of Pharmacy, Institute for Drug Safety Sciences, University of North Carolina, Chapel Hill, NC, USA.

出版信息

Drug Saf. 2018 Dec;41(12):1431-1437. doi: 10.1007/s40264-018-0745-0.

DOI:10.1007/s40264-018-0745-0
PMID:30328587
Abstract

In the original publication of the article, the ALT and AST values in Fig. 5a-e were capped at 10× ULN, which did not accurately reflect the narrative provided for each case. In this correction, the original Fig. 5a-e (Fig. 1a-e) and the correct Fig. 5a-5e (Fig. 2a-e) are published.

摘要

相似文献

1
Correction to: Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
Drug Saf. 2018 Dec;41(12):1431-1437. doi: 10.1007/s40264-018-0745-0.
2
Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.他格列汀(TAK-875)治疗 2 型糖尿病患者的肝脏安全性:全球临床试验经验回顾。
Drug Saf. 2018 Jun;41(6):625-640. doi: 10.1007/s40264-018-0642-6.
3
Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury.法格列净(TAK-875)抑制肝胆转运体:可能是导致法格列净引起肝损伤的一个因素。
Drug Metab Dispos. 2015 Nov;43(11):1751-9. doi: 10.1124/dmd.115.064121. Epub 2015 Aug 14.
4
Correction to: Two different therapies for the middle turbinate during endoscopic sinus surgery for chronic rhinosinusitis.对《慢性鼻窦炎鼻内镜手术中中鼻甲的两种不同治疗方法》的更正
Eur Arch Otorhinolaryngol. 2020 Nov;277(11):3091-3093. doi: 10.1007/s00405-020-06234-x.
5
Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875)-induced acute liver injury in mice.比较肝转录组分析揭示了法昔洛韦(TAK-875)诱导的小鼠急性肝损伤的可能发病机制。
Chem Biol Interact. 2018 Dec 25;296:185-197. doi: 10.1016/j.cbi.2018.09.011. Epub 2018 Sep 20.
6
Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.对以下内容的更正:赫赛汀β1驱动他莫昔芬耐药的MCF-7乳腺癌细胞中的吉非替尼耐药生长和侵袭。
Breast Cancer Res. 2018 Aug 30;20(1):98. doi: 10.1186/s13058-018-0999-6.
7
[Corrigendum] TLR4-mediated NF-κB signaling pathway mediates HMGB1-induced pancreatic injury in mice with severe acute pancreatitis.[勘误]Toll样受体4(TLR4)介导的核因子κB(NF-κB)信号通路介导高迁移率族蛋白B1(HMGB1)诱导的重症急性胰腺炎小鼠胰腺损伤。
Int J Mol Med. 2016 Oct;38(4):1313. doi: 10.3892/ijmm.2016.2707. Epub 2016 Aug 17.
8
Correction to: The role of melatonin in the onset and progression of type 3 diabetes.对《褪黑素在3型糖尿病发病及进展中的作用》的更正
Mol Brain. 2017 Dec 8;10(1):59. doi: 10.1186/s13041-017-0333-8.
9
Correction to: The RNA binding protein RBMS3 inhibits the metastasis of breast cancer by regulating Twist1 expression.对《RNA结合蛋白RBMS3通过调控Twist1表达抑制乳腺癌转移》一文的更正
J Exp Clin Cancer Res. 2020 Jan 27;39(1):21. doi: 10.1186/s13046-019-1509-0.
10
Publisher Correction: Fgf10 is essential for limb and lung formation.出版商更正:Fgf10对肢体和肺部形成至关重要。
Nat Genet. 2019 May;51(5):921. doi: 10.1038/s41588-019-0396-9.

引用本文的文献

1
In Silico Searching for Alternative Lead Compounds to Treat Type 2 Diabetes through a QSAR and Molecular Dynamics Study.通过定量构效关系和分子动力学研究在计算机上寻找治疗2型糖尿病的替代先导化合物
Pharmaceutics. 2022 Jan 19;14(2):232. doi: 10.3390/pharmaceutics14020232.